Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

Essential thrombocythemia (ET) was first described in 1934, and subsequently, progress has been made in better understanding the molecular pathogenesis and which patients may have greatest risk of progression or vascular events. However, it has been more than a decade since a new therapy has been approved for ET. We are beginning to understand more comprehensively both the heterogeneity of this disease, which is largely driven by driver mutation status, as well as the effect of disease-related symptoms, such as fatigue, on patients. In this review we provide a practical overview of diagnosis and management of ET with focus on challenging patient scenarios and some consideration of what comprehensive care might entail. Finally, we also discuss newer therapies and how these might be assessed. © 2023 by The American Society of Hematology.


Anna L Godfrey, Anna C Green, Claire N Harrison. Essential thrombocythemia: challenges in clinical practice and future prospects. Blood. 2023 Apr 20;141(16):1943-1953

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 36379024

View Full Text